Plain-English translation of NCT06509568 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two different ways to treat advanced esophageal cancer before surgery. Both approaches use chemotherapy drugs combined with either radiation therapy or a drug called tislelizumab (an immunotherapy that helps your immune system fight cancer). The trial wants to see which combination works better at shrinking tumors and helping patients have better outcomes after surgery.
Earlier research showed that combining chemotherapy, radiation, and immunotherapy before surgery helped about 60% of patients achieve complete tumor response. This trial exists to compare that approach head-to-head with chemotherapy combined with immunotherapy alone, to learn which strategy gives patients the best chance of success.
You likely qualify if…
You likely don't qualify if…
After screening tests confirm you qualify, you'll be randomly assigned to one of two treatment groups. If assigned to the first group, you'll receive weekly chemotherapy combined with radiation therapy for five weeks, followed by two doses of immunotherapy, then surgery about four weeks later. If assigned to the second group, you'll receive two cycles of chemotherapy mixed with immunotherapy over a shorter timeframe, then surgery 4-6 weeks later. Throughout this process, you'll have regular appointments for imaging scans, blood tests, and doctor visits to monitor your progress.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China